On March 17, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team. Learn more about this exciting combination at www.Actavis.com.
Compliance and Ethics
Allergan has long been committed to providing quality products that improve patients’ lives. Compliance and ethics are a cornerstone of who we are and what we do. Our Board of Directors and senior leadership are committed to maintaining our ethical culture and give their unwavering support to our global Corporate Compliance Program. At Allergan, we recognize that success is built on integrity and we hold ourselves to the highest ethical standards. That is good business, and it is the only business we know.